Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Receivables (2024 - 2025)

Crinetics Pharmaceuticals (CRNX) has 2 years of Receivables data on record, last reported at $8.4 million in Q4 2025.

  • For Q4 2025, Receivables changed 0.48% year-over-year to $8.4 million; the TTM value through Dec 2025 reached $8.4 million, changed 0.48%, while the annual FY2025 figure was $8.4 million, 0.48% changed from the prior year.
  • Receivables reached $8.4 million in Q4 2025 per CRNX's latest filing, roughly flat from $8.3 million in the prior quarter.
  • Across five years, Receivables topped out at $8.4 million in Q4 2025 and bottomed at $8.3 million in Q4 2024.